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In seaRch of lost costs: the IMPlIcatIons foR cost-effectIveness 
ReseaRch when the PRIce Isn’t RIght
Lupinetti P.1, Suko J.1, Johnson T.1, Matuszewski K.2
1First Databank, South San Francisco, CA, USA, 2First Databank
Objectives: Analyses of drug cost-effectiveness have traditionally been based 
on two key components: effectiveness measured by clinical endpoints reported 
in product label or biomedical literature, and cost obtained from available pricing 
sources. While the former is a relatively well-defined value derived from pivotal 
trials and subsequent studies, the latter has often not been well-described or rigor-
ously assessed, and may be based upon manufacturer-reported pricing information 
that has been shown to be inaccurate and unreliable. This study examines existing 
benchmarks against newly available sources of pharmaceutical pricing, describes 
their interrelationships and assesses their stability over time. MethOds: Using 
publicly available cost data for wholesale acquisition cost (WAC), average manu-
facturer price (AMP), national average drug acquisition cost (NADAC), AMP-based 
federal upper limit (FUL), and a composite of six states’ average acquisition cost 
(AAC), mean, median, and standard deviation values were calculated for a broad 
range of pharmaceuticals and trade classes (brand vs. generic) and analyzed tem-
porally for trend and consistency patterns. Results: Available pricing data reflects 
an extremely high degree of variability and inconsistent relationships, both between 
equivalent products and from one price type to another. Generic drug prices demon-
strated the greatest irregularity, and although the ratio of NADAC or AMP to WAC for 
branded drugs showed correlations overall, for given products those relationships 
could be substantially at variance. cOnclusiOns: Continuing review and analysis 
of all available price types is needed to identify a reliable drug pricing benchmark 
that permits reviewers and clinicians to determine the optimal course of treatment. 
Since reported ratios may shift over time, future reports of cost-effectiveness must 
explicitly identify the cost basis employed and its reliability for the products at issue.
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a RevIew of nIce technology aPPRaIsals usIng sIngle-aRM tRIals
Purser M.1, Mladsi D.M.1, Wolowacz S.2
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Objectives: Head-to-head randomized controlled trials (RCTs) remain the gold 
standard for establishing relative treatment efficacy and for use in cost-effective-
ness (CE) models. However, in some cases, such as rare diseases, only single-arm 
trials may be available. We identified health technology appraisals (HTAs) published 
by the National Institute for Health and Care Excellence (NICE) that included evi-
dence from single-arm trials and reviewed the use of the single-arm trial data in 
accompanying CE models. MethOds: We searched the NICE website for published 
technology appraisals using the term “single-arm”. We reviewed HTAs in which 
single-arm trials were used and recorded the date of the appraisal, disease area, use 
of the single-arm trial data, the NICE recommendation, and NICE’s comments on 
the use of the single-arm trials. Results: Twenty-two HTAs included a reference 
to one or more single-arm trials. Fourteen provided the single-arm trial data only 
as supporting evidence to at least one RCT. Of the eight that used single-arm trial 
data, all also used the data in a model; four used the data as the primary evidence of 
efficacy, two used the data to extend an RCT, and two used the data for other inputs. 
Only one of the four using the data for evidence of efficacy resulted in a positive 
recommendation from NICE. In this case, evidence was from seven single arm trials; 
two manufacturer models and the assessment group model all demonstrated the 
intervention to be dominant over standard care, and several other factors may have 
contributed to a positive recommendation. In the three HTAs resulting in a negative 
recommendation, NICE expressed concerns over the efficacy data. cOnclusiOns: 
Although RCTs are preferred for relative efficacy data for use in cost-effectiveness 
analyses in NICE HTAs, there is one case of a positive NICE recommendation despite 
efficacy evidence being based on single-arm trials.
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Objectives: Efficiency may be crucial to a health technology’s value proposition. 
Measuring time endpoints prospectively is subject to variability and bias that 
makes Time and Motion (T&M) methodology complex. The aim was to investi-
gate key design characteristics of T&M studies recently presented at ISPOR con-
ferences. MethOds: A search was performed in ScienceDirect, using “time and 
motion” as key term, restricted to ‘Value in Health’ journal for the years 2008-2013 
to identify all ISPOR conference presentations during that period. Presentations 
were excluded based on the following criteria: (1) not a T&M study; (2) not present-
ing T&M results. Results: Of 116 abstracts, 29 complied with inclusion criteria; 8 
presentations could not be obtained; 7 were later excluded; 14 were retained for 
detailed assessment: 11 were observational studies, 2 reported survey data, and 1 
was a simulation study. Distribution of interventions being studied was: drug (43%), 
medical supply (29%), device (14%), and procedure (14%). 64% were conducted in 
Europe and 43% were multi-country. Primary objective of 13 studies was measuring 
process time (one only focused on cost); 57% also reported cost results. 13 studies 
measured time for tasks composing a process in a hospital setting with number 
of tasks ranging from 2 to 8; one study measured HCP workload. 85% investigated 
two processes (15% 3-4), but none were comparative studies powered to test a 
hypotheses of time differences between groups. 43% reported inferential statistics 
(e.g. covariance analyses, 95% CIs). One study applied a multilevel model to test 
centre clustering. cOnclusiOns: This T&M study review reveals a clear choice for 
descriptive non-hypotheses testing designs; some employ inferential statistics. In 
multi-centre studies, multilevel models to account for “centre clustering” are scarce. 
sions have been reached. This study sought to assess the relationship between 
Body Mass Index (BMI) and health care costs using 2006-2010 data from the Medical 
Expenditure Panel Survey (MEPS). MethOds: Eligible patients were ≥ 18 years, with 
a diabetes diagnosis (CCC-250) and on at least one oral antidiabetic medication. 
Primary outcomes were: 1) diabetes-related direct medical costs, 2) all-cause direct 
medical costs, and 3) indirect costs. Costs were inflated to 2010 US dollars using the 
medical consumer price index. The main independent variable was BMI, categorized 
as normal weight BMI: 18.0-24.9; overweight BMI: 25.0-29.9; obese BMI: 30.0-40.0; 
and morbidly obese BMI: > 40.0 kg/m2. Covariates included demographic and clinical 
variables. Generalized linear models with gamma distribution and log link function 
were conducted. Results: A final unweighted sample size of 7,003 patients was 
obtained (14.6 million weighted), with a mean age (±SE) = 61.2 (±0.2) years, mean BMI 
(±SE) = 32.2 (±0.1), and 50.4% were males. After controlling for covariates, diabetes-
related direct medical costs of normal-weight patients ($1,622) were lower than their 
overweight ($1,955; p= 0.031), obese ($2,259; p= 0.001) and morbidly obese ($2,636; 
p= 0.003) peers. But direct all-cause medical costs of overweight patients were less 
($9,715; p= 0.021) compared to normal weight ($11,623) patients. All-cause direct 
costs for obese ($11,419) and morbidly obese ($13,043) patients were not statisti-
cally different than costs for normal weight peers. Indirect costs (estimated as lost 
productivity) were similar between all 4 cohorts ($532-$535). cOnclusiOns: Being 
overweight (BMI = 25.0 to 29.9 kg/m2) was associated with higher diabetes-related 
direct medical costs, but lower all-cause direct medical costs compared to their 
normal weight peers.
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Objectives: The aim of the study is to assess the long-term economic value of one 
additional child born in Hungary, Italy, Spain, Sweden and the UK. MethOds: Two 
different methodologies are applied. The Human Capital Approach representing 
the perspective of the society is used to estimate the potential loss in production 
for every unborn child. It is calculated by summing up the discounted value of 
all expected future gross earnings of the individual, including an imputed value 
for household production. The Lifetime Investment Approach representing the 
point of view of the government is used to calculate the impact of an additional 
child on the fiscal balance. Expected revenues from taxes and social contributions 
and expected public expenditures (e.g. education, health, pension, etc.) for the 
lifetime of average person are calculated. The net balance is discounted to obtain 
the present value. Input data is obtained from the statistical databases of the 
OECD and EUROSTAT and from own calculations. Results are presented as a per-
centage of GDP per capita for 2012. Results: Preliminary results indicate that 
there is great heterogeneity between countries in the values of one additional 
child born. The present value of future earnings according to the Human Capital 
Approach indicates that a child will produce 11 to 21 times the 2012 GDP per 
capita during his lifetime. According to the Lifetime Investment Approach, an 
average child will contribute 3.4 and 6.0 times the GDP per capita of government 
revenues by the end of his lifetime. cOnclusiOns: The two methods used pre-
sent gains (or losses) of an additional child from the perspective of the society 
as well as from the point of view of the sustainability of public finances. Results 
vary by country. Therefore, it is essential that such calculations are performed on 
a country-by-country bases.
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Objectives: To use baseline results from a prospective observational study in 
Alzheimer’s disease (AD) to evaluate methods for dealing with missing longi-
tudinal AD cost data. MethOds: GERAS is an 18-month observational study of 
costs associated with AD. Total societal costs included patient health care costs 
(including hospitalizations, outpatient visits, and medication) and social care costs 
(including home-care and day-center sessions), and caregiver informal care costs 
(from time spend on informal care). Missing longitudinal cost data due to patient 
death/institutionalization was classified as not missing at random (NMAR). Cost 
data missing for other reasons was classified as missing at random (MAR) or 
missing completely at random (MCAR). To assess the impact of imputing missing 
longitudinal cost data, patterns of missing data during follow-up were simulated 
based on baseline GERAS data to generate 10%, 20%, 30% and 40% missing data for 
MCAR, MAR and NMAR classifications. Naïve methods (including complete case 
analysis, mean imputation and regression models), multiple imputation (MI) and 
a fixed cost were applied to each dataset and %bias assessed using (estimated-
actual)/actual cost*100. Results: Total baseline societal costs were available for 
1488 (99.4%) of enrolled patients, with a mean monthly cost of € 2101(95% CI: 
€ 1980-€ 2222). For MCAR datasets, naïve methods performed as well as MI (20% 
missing data: 0.6-10.9% bias naïve methods vs 0.2-6.1% MI). For MAR data, MI 
methods performed better (-3.2% to -14.3% bias) than naïve methods (6.6%-18.0% 
bias). All approaches were consistently poor with NMAR data (bias range -31.4% to 
-38.6%); the best performing approach was to impute a fixed value (monthly cost 
of institutionalisation) with -22.6% bias. For all approaches %bias increased with 
missing data volume. cOnclusiOns: Methods used to impute missing cost data 
in AD should be tailored depending on the type of missing data, using sensitivity 
analysis to assess the impact of any assumptions.
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GLM and multistate models, is that it adjusts for the two main sources of bias. 
Estimates obtained through this method are within the range defined by the other 
two approaches. We propose that this new method provides more accurate esti-
mates of the actual economic burden of HAIs.
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PeRfoRMance coMPaRIson of dIffeRent tyPes of PRoPensIty scoRe 
MatchIng algoRIthMs In a study of RaRe dIsease tReatMent cost 
coMPaRIson usIng Real woRld evIdence
Han Y., Lodowski N.
WG Consulting, New York, NY, USA
Objectives: It is well-accepted that data pre-processing and the creation of 
matching cohorts may provide a more balanced assessment in real world evidence 
analysis. The objective of this study is to show that proper selection of a propensity 
score matching (PSM) algorithm can significantly enhance the sensitivity of treat-
ment cost comparison for rare diseases using claims databases. MethOds: Five 
years of retrospective inpatient commercial insurance claims data from Truven 
MarketScan™ were used to compare the six-month drug cost of ‘Drug X’ to ‘Drug 
Y’ for a rare disease, with Drug Y being the market leader. Within this study, three 
different types of PSM techniques were used (naïve matching, logit and recursive 
partitioning) to determine the impact of matching algorithms on the sensitivity of 
final comparison. A 2:1 matching ratio was used to take advantage of much larger 
patient pool for Drug Y. Results: Without PSM, the difference in cost of the two 
treatments was not statistically significant, although these results show that the 
spending for Drug X patients is approximately $220 less than Drug Y users over a 
6 month period. In the naïve matching method, the drug cost of treatment X was 
$234 lower than treatment Y, although the observed difference was not statistically 
significant. Using the logit regression algorithm, it was found that the mean cost 
of Drug X was approximately $368 lower than Drug Y (p= 0.028). Lastly, with non-
linear recursive partitioning PSM, the treatment cost of Drug X was $351 lower than 
Drug Y (p= 0.045). cOnclusiOns: The use of PSM in studies can help to remove 
potential confounders and produce unbiased results. Model-based PSM outperforms 
naïve matching in terms of enhancing analysis sensitivity. The careful selection of 
a matching algorithm can play a pivotal role in economic investigations for rare 
diseases using real world evidence.
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oPPoRtunIty foR non-InvasIve seRuM oR IMagIng bIoMaRkeRs fRoM a 
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Agnese W., Suciu S., Liu S., Sood V., Cooreman M.
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Objectives: Non-alcoholic Steatohepatitis (NASH) is the hepatic manifestation of 
metabolic syndrome with an increasing prevalence globally. Although there are no 
currently approved treatments, NASH therapeutic research and development efforts 
are ongoing, targeting multiple aspects of the complex disease pathways. Halting or 
reversing inflammation and progressive liver fibrosis are core endpoints to evaluate 
therapeutic efficacy. The choice of diagnostic tool may have implications on the 
length of study and related costs. MethOds: We sought to evaluate current studies 
on www.clinicaltrials.gov using search term ‘NASH’, and assess efficacy outcomes, 
related length of clinical programs, and research activities in relation to epidemiol-
ogy. We included studies in our analysis that were: “Interventional, Phase 2, 3, or 4, 
known status”, from Europe or North America, and NASH fibrosis and/or inflam-
mation, not related to viral infection. We estimated current development costs, 
and applied alternative biomarker composite endpoints, to assess potential cost 
and time savings. Results: As of January 2014, there are 199 NASH studies posted 
to clinicaltrials.gov, of which 54 studies met our criteria. Thirty seven of those 54 
studies use histology (liver biopsy) as the primary endpoint at a mean timepoint of 
58.5 weeks, compared to 18.1 weeks when non-invasive diagnostic methods (serum 
markers of inflammation and fibrosis, imaging) are used (p< 0.0001). cOnclusiOns: 
Our data show that utilization of non-invasive markers as primary efficacy end-
points can allow for clinical trials of considerably shorter duration which may have 
an impact on cost-efficiency of clinical development programs for NASH. Further 
study is required to expand upon these findings as well as validate biomarkers for 
acceptable use in registrational trials.
ReseaRch on Methods – databases & Management Methods
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alcohol and substance use dIsoRdeR coMoRbIdIty MeasuRes: who Is 
beIng counted?
Montejano L.B.
Truven Health Analytics, Cambridge, MA, USA
Objectives: Patients with comorbid alcohol use disorders (AUD) and substance 
use disorders (SUD) may be identified in administrative claims data using a range 
of codes (eg ICD-9 303-305), but it is not clear this yields a homogenous group. 
The objective of this study was to characterize patients with AUD/SUD claims to 
better understand the resulting comorbidity measures. MethOds: Patients with 
≥ 1 claim indicative of AUD/SUD between 2005-2012 were identified in the Truven 
Health MarketScan® Commercial and Medicare Research Databases. Continuous 
enrollment 6 months before and 12 months after the earliest AUD/SUD claim was 
required. Patients were analyzed overall, then stratified by earliest drug of abuse 
(alcohol, amphetamines, cannabis, cocaine, hallucinogens, sedatives, opioids) for 
bivariate comparison of patient characteristics, cost and utilization. Results: The 
sample included 476,628 patients; most (73%) with an AUD diagnosis. Overall, the 
sample was mean age 39 and 63% male. Total post-index costs were mean $17,481 
and median $7,332. Other cost measures were similarly skewed. Less than half 
(43%) had a second AUD/SUD claim ≥ 30 days post-index. The sedative cohort had 
Consideration of the causes of variability and appropriate statistical analyses to 
generate unbiased estimators and reliable confidence intervals remains a chal-
lenge for these studies.
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what aRe IndIRect costs In neuRodegeneRatIve dIseases? a 
MethodologIcal RevIew
Costa N., Deruemaux-Burel H., Molinier L.
University Hospital of Toulouse, Toulouse, France
Objectives: Neurodegenerative diseases (NDs) refer to a group of diseases that 
affect brain cells. Alzheimer disease (AD), Parkinson disease (PD), Amyotrophique 
Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) are the most prevalent NDs. NDs 
cause a substantial economic burden worldwide and indirect costs are an important 
component of total costs. This study aims to review relevant papers to characterize 
the different components of indirect costs and to identify the weight of indirect 
costs on total costs in different NDs. MethOds: A systematic bibliographic search 
was performed on an international medical literature database (MEDLINE). All stud-
ies which assessed the social economic burden and indirect costs of different NDs 
were selected. Indirect costs were characterized into several types (i.e. sick leave, 
presenteeism, early retirement, premature death, reduction in working hours, infor-
mal care time) and into several valuation (i.e. Human Capital Approach, Friction Cost 
Method, Willingness To Pay). Results: 44 studies met our criteria. Depending on 
studies, the percentage of indirect costs on total costs varies from 1% to 68% in PD, 
from 2% to 89% in AD, from 24% to 59% in ALS and from 29% to 78% in MS. The main 
indirect costs component was early retirement in PD, ALS and MS. This component 
varies from 61% to 95% of indirect costs in PD, from 35% to 88% in ALS and from 61% 
to 95% in MS. The main indirect costs component in AD was informal care time and 
account for almost 100% of indirect costs. Indirect costs increase with severity level 
in AD and MS, and decrease with severity level in ALS. cOnclusiOns: Components 
of indirect costs are different depending on studies and especially for AD where 
indirect costs mainly refer to informal costs which should be considered as a full 
cost category to avoid the lack of understanding.
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Objectives: In this study we explore the methodological challenges presented by 
retrospective economic analyses of vaccination programs and offer direction for 
future evaluations in the area. Post-implementation evaluation should be an impor-
tant part of assessing the success of public health programs; however relatively 
little attention has been focused on evaluating the value for money achieved by 
vaccination programs after they have been introduced. MethOds: We conducted a 
narrative review of the limited existing economic evaluation literature assessing the 
cost-effectiveness of implemented vaccination programs. We evaluated the alterna-
tive approaches to addressing the challenges that these retrospective evaluations 
present. These challenges were then contrasted and compared with those that 
prospective economic evaluations face. Results: The key challenges identified 
for retrospective economic evaluations include the estimation of: disease changes 
attributable to vaccination efforts, the hypothetical no vaccination comparator 
scenario and the full benefits likely to be achieved by implemented vaccination 
programs. We also present other important factors that may need to be considered 
such as the evolution of prices over time. cOnclusiOns: Retrospective economic 
analyses of vaccination programs are likely to become more frequent and influential 
and it is important that both the benefits and the limitations of these evaluations 
are recognised and understood. Further work needs to be done to explore how the 
practical application of alternative approaches may impact on the results of evalu-
ations in different circumstances.
PRM30
estIMatIng the cost of health caRe assocIated InfectIons 
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Objectives: In the current health care environment, it is critical that we obtain 
better insights into the economic burden of major complications, such as health 
care associated infections (HAIs). Commonly used methods, however, are limited 
in that they provide cost and length of stay (LOS) estimates, adjusted either for 
patients’ heterogeneity (generalized linear model (GLM)) or for the time depend-
ency of HAIs (multistate model), but don’t allow adjustment for both. We developed 
an approach that controls for both of these major confounders. MethOds: Our 
approach uses centered residuals from a GLM that account for important covariates. 
These residuals are then used in a multistate model to estimate the extra-LOS cor-
rected for the lead time. To obtain the dollar value, the extra-days were multiplied 
by the average cost of a post-infection day. We applied GLM, multistate and our 
new approach to a prospective multicenter observational study, assessing the inci-
dence of HAIs in cardiac surgery. Financial data were obtained from the University 
Health Consortium. Results: Among 4320 patients, 119 (2.7%) developed major 
infections during index hospitalization. Patients developing major infection after 
their surgery had longer and costlier hospitalizations than patients who did not (33 
days and $110,155 vs. 9 days and $31,530).The extra-cost and LOS due to HAIs were 
calculated using the three approaches. The new approach yields estimates ($34,632 
and 13 days) that are intermediate between those obtained from GLM ($37,922 and 
14 days) and multistate modeling ($29,304 and 11days). Results of simulations will 
be presented. cOnclusiOns: The advantage of our approach, which combines 
